Edison Investment Research - Osirium Technologies (OSI) Osirium Technologies - Positive order momentum in Q4

Report

Edison Investment Research

Richard Williamson

Osirium Technologies - Positive order momentum in Q4

Osirium expects to report FY20 bookings ahead of our forecast, with revenue for the year in line. The flurry of contracts announced in Q4 reflects the pick-up in order activity after COVID-19 depressed activity in Q2/Q3. Management is confident that the momentum achieved in Q4 will continue into FY21. We maintain our forecasts pending FY20 results.

15/01/2021 2 EN

Underlying

Osirium Technologies

Osirium Technologies and its subsidiary are engaged as a U.K. based cyber-security software provider that protects critical information technology ("IT") assets, infrastructures and devices by preventing targeted cyber-attacks from directly accessing Privileged Accounts, removing unnecessary access and powers of Privileged Account users, deterring legitimate Privileged Account users from abusing their roles and containing the effects of a breach if one does happen.

See profile

GB00BZ58DH10 London Stock Exchange United Kingdom

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Richard Williamson

Other Reports on these Companies

Edison Investment Research

Osirium Technologies - Termination of coverage

Edison Investment Research is terminating coverage on Avon Protection (AVON), Osirium Technologies (OSI), IQE (IQE), Kopy Goldfields (KOBY) and RhoVac (ROHVAC). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

May 31, 2022 May 31, 2022 1 EN

Edison Investment Research

Osirium Technologies - Accelerating bookings

Osirium reported a relatively flat year for bookings and revenue in FY21, although this masks the doubling of the customer base over the year. As customer decision-making returns to pre-pandemic norms, we expect accelerating growth in bookings. The company has made a strong start to the year with record order intake in Q122. We maintain our FY22 forecasts.

April 22, 2022 April 22, 2022 1 EN

Edison Investment Research

Osirium Technologies - Positive Q1 update

Following on from its positive early-March update, Osirium confirms that strong order momentum continued to the end of Q122, resulting in a record bookings quarter. The company is seeing growth in contract values as customers expand usage and increasingly adopt Osirium’s wider privileged access security suite. Order intake year to date gives the board confidence in the full year outlook. We maintain our forecasts.

April 5, 2022 April 5, 2022 1 EN

Headlam Group - Strategy for growth in tougher market

Headlam Group has laid out an ambitious long-term revenue target of between £900m and £1bn, as it seeks to grow its share of the UK floor coverings distributor market. Despite a challenging backdrop due to the low level of residential housing transactions, management is seeking to expand each of its sales channels: Trade Counters, Larger Customers, Regional Distribution and Europe & Other. The FY23 results reflected the more challenging environment and the group trades at a discount to its long-term average EV/sales multiple for FY24.

18h / 3m 18h / 3m 1 EN

Alison Turner

Alison Turner

Lithium Power International - Termination of coverage

Edison Investment Research is terminating coverage on ABC Arbitrage (ABCA), paragon (PGN), Foresight Solar Fund (FSFL), Kendrion (KENDR), Lithium Power International (LPI), Triple Point Energy Transition (TENT), 4iG (4IG), e-therapeutics (ETX), Pharnext (ALPHA) and Shield Therapeutics (STX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.

18h / 40m 18h / 40m 1 EN

Toby Thorrington

Toby Thorrington

paragon - Termination of coverage

18h / 40m 18h / 40m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Osirium Technologies - Positive order momentum in Q4

Osirium Technologies - Termination of coverage

Osirium Technologies - Accelerating bookings

Osirium Technologies - Positive Q1 update

Headlam Group - Strategy for growth in tougher market

Lithium Power International - Termination of coverage

paragon - Termination of coverage

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe